Search Result

Results for "

amyloid

" in MCE Product Catalog:

By Targets:	Amyloid-β (134) 5-HT Receptor (2) Acyltransferase (1) Adenosine Deaminase (1) Adrenergic Receptor (1) Amino Acid Derivatives (1) Amylin Receptor (1) Antibiotic (3) Apoptosis (16) ATM/ATR (1) Autophagy (11) Bacterial (5) Beta-secretase (14) Calcium Channel (1) Caspase (2) CDK (2) Cholinesterase (ChE) (14) DNA/RNA Synthesis (1) Dopamine Receptor (2) DYRK (1) EGFR (2) Endogenous Metabolite (4) Estrogen Receptor/ERR (1) Fluorescent Dye (5) Formyl Peptide Receptor (FPR) (2) Fungal (3) GABA Receptor (1) GCGR (2) Glucosidase (1) GSK-3 (3) Histamine Receptor (3) HIV (3) iGluR (1) IKK (3) Interleukin Related (2) Isotope-Labeled Compounds (1) JNK (2) Keap1-Nrf2 (5) mAChR (2) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitophagy (3) MMP (1) Monoamine Oxidase (5) mTOR (2) nAChR (2) Neuropeptide Y Receptor (3) NF-κB (6) NOD-like Receptor (NLR) (4) Notch (2) Nucleoside Antimetabolite/Analog (3) p38 MAPK (1) PAI-1 (1) Phosphatase (1) Phosphodiesterase (PDE) (1) Potassium Channel (1) Ras (1) Reactive Oxygen Species (1) Reverse Transcriptase (3) ROS Kinase (1) Sirtuin (3) Tau Protein (1) Transthyretin (TTR) (2) α-synuclein (1) γ-secretase (11)
By Research Areas:	Cancer (17) Cardiovascular Disease (3) Endocrinology (3) Infection (8) Inflammation/Immunology (18) Metabolic Disease (6) Neurological Disease (177)

By Targets:

Amyloid-β (134)

5-HT Receptor (2)

Acyltransferase (1)

Adenosine Deaminase (1)

Adrenergic Receptor (1)

Amino Acid Derivatives (1)

Amylin Receptor (1)

Antibiotic (3)

Apoptosis (16)

ATM/ATR (1)

Autophagy (11)

Bacterial (5)

Beta-secretase (14)

Calcium Channel (1)

Caspase (2)

CDK (2)

Cholinesterase (ChE) (14)

DNA/RNA Synthesis (1)

Dopamine Receptor (2)

DYRK (1)

EGFR (2)

Endogenous Metabolite (4)

Estrogen Receptor/ERR (1)

Fluorescent Dye (5)

Formyl Peptide Receptor (FPR) (2)

Fungal (3)

GABA Receptor (1)

GCGR (2)

Glucosidase (1)

GSK-3 (3)

Histamine Receptor (3)

HIV (3)

iGluR (1)

IKK (3)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

JNK (2)

Keap1-Nrf2 (5)

mAChR (2)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

Mitophagy (3)

MMP (1)

Monoamine Oxidase (5)

mTOR (2)

nAChR (2)

Neuropeptide Y Receptor (3)

NF-κB (6)

NOD-like Receptor (NLR) (4)

Notch (2)

Nucleoside Antimetabolite/Analog (3)

p38 MAPK (1)

PAI-1 (1)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

Potassium Channel (1)

Ras (1)

Reactive Oxygen Species (1)

Reverse Transcriptase (3)

ROS Kinase (1)

Sirtuin (3)

Tau Protein (1)

Transthyretin (TTR) (2)

α-synuclein (1)

γ-secretase (11)

By Research Areas:

Cancer (17)

Cardiovascular Disease (3)

Endocrinology (3)

Infection (8)

Inflammation/Immunology (18)

Metabolic Disease (6)

Neurological Disease (177)

210

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas

HY-P1474

*β-Amyloid* (22-35)** amyloid β-Protein (22-35)	Amyloid-β	Neurological Disease
β-Amyloid 22-35 (Amyloid β-Protein 22-35), the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution).

HY-P1474A

*β-Amyloid* (22-35) (TFA)** amyloid β-Protein (22-35) (TFA)	Amyloid-β	Neurological Disease
β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution).

HY-P3779

Amyloid 17-42 Aβ(17-42)	Apoptosis	Neurological Disease
Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of *the amyloid* precursor protein (APP)*. Amyloid* 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway.

HY-P1046

*β-Amyloid* (1-15)** amyloid β-Protein (1-15)	Amyloid-β	Neurological Disease
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1468

*β-Amyloid* (1-28)** amyloid β-Protein (1-28)	Amyloid-β	Neurological Disease
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1466

*β-Amyloid* (1-16)** amyloid β-Protein (1-16)	Amyloid-β	Neurological Disease
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1522

β-Amyloid (29-40)
amyloid beta-protein(29-40)
Amyloid-β Neurological Disease

β-Amyloid (29-40) is a fragment of Amyloid-β peptide.

*β-Amyloid* (29-40)** amyloid beta-protein(29-40)	Amyloid-β	Neurological Disease
β-Amyloid (29-40) is a fragment of Amyloid-β peptide.

HY-P1051

*β-Amyloid* (12-28)** amyloid β-Protein (12-28)	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research.

HY-P0128

*β-Amyloid* (25-35)** amyloid beta-peptide (25-35); Aβ25-35; β-amyloid peptide (25-35)	Amyloid-β	Neurological Disease
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.

HY-P1362

*β-Amyloid* (42-1), human** amyloid β Peptide (42-1)(human)	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

HY-P1051A

*β-Amyloid* (12-28) (TFA)** amyloid β-Protein (12-28) (TFA); amyloid Beta-Peptide (12-28) (human) TFA; β-amyloid protein fragment(12-28) TFA	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (TFA) (Amyloid β-Protein (12-28) (TFA)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) (TFA) shows aggregation properties. β-Amyloid (12-28) (TFA) has the potential for Alzheimer’s disease research.

HY-P1362A

*β-Amyloid* (42-1), human TFA** amyloid β Peptide (42-1)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

HY-19771

amyloid P-IN-1	Amyloid-β	Cancer
amyloid P-IN-1 is used in the research of diseases or disorders wherein depletion of serum amyloid P component (SAP), including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.

HY-P3793

Amyloid β-Protein (33-42) (TFA)	Amyloid-β	Neurological Disease
Amyloid β-Protein (33-42) TFA is the residues 33-42 fragment of the β-amyloid protein. Amyloid β-Protein (33-42) TFA inhibits Aβ42-induced toxicity.

HY-P0265AS

*β-Amyloid-15N (1-40) (TFA)* amyloid Beta-Peptide-¹⁵N (1-40) (human) (TFA); amyloid β-Peptide-15N (1-40) (human) (TFA)	Amyloid-β	Neurological Disease
β-Amyloid- 15N (1-40) (TFA) is the ¹⁵N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease[1].

HY-P1363

*β-Amyloid* (1-42), human TFA** amyloid β-Peptide (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

HY-P1363S

*β-Amyloid-15N (1-42), human TFA* amyloid β-Peptide-¹⁵N (1-42) (human) (TFA)	Amyloid-β	Neurological Disease
β-Amyloid- 15N (1-42), human (TFA) is the ¹⁵N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease[1].

HY-P0265A

*β-Amyloid* (1-40) (TFA)** amyloid Beta-Peptide (1-40) (human) TFA; amyloid β-Peptide (1-40) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-40) TFA is a primary protein in plaques found in the brains of patients with Alzheimer's disease.

HY-50900

gamma-Secretase Modulators amyloid-β production inhibitor; γ-Secretase Modulators	Amyloid-β	Neurological Disease
gamma-Secretase Modulators (Amyloid-β production inhibitor) is a Amyloid-β production inhibitor.

HY-P1388

*β-Amyloid* (1-42), (rat/mouse)** amyloid β-peptide (1-42) (rat/mouse)	Amyloid-β	Neurological Disease
β-Amyloid (1-42), (rat/mouse) is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.

HY-P1388A

*β-Amyloid* (1-42), (rat/mouse) (TFA)** amyloid β-peptide (1-42) (rat/mouse) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42), (rat/mouse) TFA is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.

HY-P3858

*(D-Asp1)-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
(D-Asp1)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease.

HY-P3909

*Biotinyl-Ahx-Amyloid* β-Protein (1-42) (ammonium)**	Amyloid-β	Neurological Disease
Biotinyl-Ahx-Amyloid β-Protein (1-42) ammonium is a N-terminally biotin-labeled Amyloid β-Protein (1-42). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease.

HY-P3782

(Met(O2)35)-Amyloid β-Protein (1-42)
Amyloid-β Others

(Met(O2)35)-Amyloid β-Protein (1-42) is a peptide.

*(Met(O2)35)-Amyloid* β-Protein (1-42)**	Amyloid-β	Others
(Met(O2)35)-Amyloid β-Protein (1-42) is a peptide.

HY-P3859

*Cys-Gly-Lys-Arg-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) can be used in research of Alzheimer's disease.

HY-P3780

*Cys-Gly-Lys-Lys-Gly-Amyloid* β-Protein (36-42)**	Amyloid-β	Neurological Disease
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment.

HY-P1521

β-Amyloid (15-21)
Beta-amyloid (15-21)
Amyloid-β Neurological Disease

β-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.
HY-P1880

β-Amyloid (12-20)
Amyloid-β Neurological Disease

β-Amyloid (12-20) is a peptide fragment of β-Amyloid.
HY-P1891

β-Amyloid (22-40)
Amyloid-β Neurological Disease

β-Amyloid (22-40) is a peptide fragment of β-Amyloid.
HY-P1879

β-Amyloid (18-28)
Amyloid-β Neurological Disease

β-Amyloid (18-28) is a peptide fragment of β-Amyloid.
HY-P1893

β-Amyloid (11-22)
Amyloid-β Neurological Disease

β-Amyloid (11-22) is a peptide fragment of β-Amyloid.

*β-Amyloid* (15-21)** Beta-amyloid (15-21)	Amyloid-β	Neurological Disease
β-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.

*β-Amyloid* (12-20)**	Amyloid-β	Neurological Disease
β-Amyloid (12-20) is a peptide fragment of β-Amyloid.

*β-Amyloid* (22-40)**	Amyloid-β	Neurological Disease
β-Amyloid (22-40) is a peptide fragment of β-Amyloid.

*β-Amyloid* (18-28)**	Amyloid-β	Neurological Disease
β-Amyloid (18-28) is a peptide fragment of β-Amyloid.

*β-Amyloid* (11-22)**	Amyloid-β	Neurological Disease
β-Amyloid (11-22) is a peptide fragment of β-Amyloid.

HY-P2551

*Biotin-β-Amyloid* (17-40)**	Amyloid-β	Neurological Disease
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-ß-(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP).

HY-P1867

β-Amyloid (1-34)
Amyloid-β Neurological Disease

β-Amyloid (1-34) is a β-Amyloid peptide consists of 34 amino acid.
HY-P1895

β-Amyloid (33-40)
Amyloid-β Neurological Disease

β-Amyloid (33-40) is a peptide consisting of amino acid of 33 to 40 of beta amyloid protein.
HY-P1903

β-Amyloid (35-42)
Amyloid-β Neurological Disease

β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.
HY-P1898

β-Amyloid (13-27)
Amyloid-β Neurological Disease

β-Amyloid (13-27) is a peptide consisting of amino acid of 13 to 27 of beta amyloid protein.

*β-Amyloid* (1-34)**	Amyloid-β	Neurological Disease
β-Amyloid (1-34) is a β-Amyloid peptide consists of 34 amino acid.

*β-Amyloid* (33-40)**	Amyloid-β	Neurological Disease
β-Amyloid (33-40) is a peptide consisting of amino acid of 33 to 40 of beta amyloid protein.

*β-Amyloid* (35-42)**	Amyloid-β	Neurological Disease
β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.

*β-Amyloid* (13-27)**	Amyloid-β	Neurological Disease
β-Amyloid (13-27) is a peptide consisting of amino acid of 13 to 27 of beta amyloid protein.

HY-P1854

*β-Amyloid* (1-9)**	Amyloid-β	Neurological Disease
β-Amyloid (1-9), an N-terminal fragment of beta amyloid, consists of amino acid residues 1 to 9. β-Amyloid (1-9) contains a B cell epitope, but it does not include T cell epitopes. Omission of residues 1 to 9 from the full-length Alzheimer'sβ-Amyloid peptide 1 to 40 does not prevent the peptide from forming amyloid fibrils or eliminate fibril polymorphism .

HY-P1510

β-Amyloid (1-11)
Amyloid-β Neurological Disease

β-Amyloid (1-11) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.
HY-P1517

β-Amyloid (31-35)
Amyloid-β Neurological Disease

β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.
HY-P1850

β-Amyloid (1-20)
Amyloid-β Neurological Disease

β-Amyloid (1-20) consists of amino acids 1 to 20 of beta amyloid protein.
HY-P2549

Biotin-β-Amyloid (1-40)
Fluorescent Dye Neurological Disease

Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-ß-(1-40) peptide.
HY-P1053

β-Amyloid (10-20)
Amyloid-β Neurological Disease

β-Amyloid (10-20) is a fragment of Amyloid-β peptide and maybe used in the research of neurological disease.
HY-P1772

β-Amyloid (1-17)
Amyloid-β Neurological Disease

β-Amyloid (1-17) is a peptide of β-Amyloid, stabilizes the fibres and plays a role in Aβ fibre formation.

*β-Amyloid* (1-11)**	Amyloid-β	Neurological Disease
β-Amyloid (1-11) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.

*β-Amyloid* (31-35)**	Amyloid-β	Neurological Disease
β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.

*β-Amyloid* (1-20)**	Amyloid-β	Neurological Disease
β-Amyloid (1-20) consists of amino acids 1 to 20 of beta amyloid protein.

*Biotin-β-Amyloid* (1-40)**	Fluorescent Dye	Neurological Disease
Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-ß-(1-40) peptide.

*β-Amyloid* (10-20)**	Amyloid-β	Neurological Disease
β-Amyloid (10-20) is a fragment of Amyloid-β peptide and maybe used in the research of neurological disease.

*β-Amyloid* (1-17)**	Amyloid-β	Neurological Disease
β-Amyloid (1-17) is a peptide of β-Amyloid, stabilizes the fibres and plays a role in Aβ fibre formation.

HY-P3845

*(Gly22)-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease. Mutation of Glu22 to Gly22 in Aβ can increase aggregation.

HY-P1524

β-Amyloid (1-14),mouse,rat
Amyloid-β Neurological Disease

β-Amyloid (1-14),mouse,rat is a 1 to 14 fragment of Amyloid-β peptide.

*β-Amyloid* (1-14),mouse,rat**	Amyloid-β	Neurological Disease
β-Amyloid (1-14),mouse,rat is a 1 to 14 fragment of Amyloid-β peptide.

HY-P3846

*(Glu20)-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease.

HY-P1387

*β-Amyloid* (1-40) (rat)**	Amyloid-β Apoptosis	Neurological Disease
β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases ⁴⁵Ca²⁺ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease.

HY-P1787

*β-Amyloid* (4-10)**	Amyloid-β	Neurological Disease
β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model.

HY-P1567

*β-Amyloid* (10-35), amide**	Amyloid-β	Neurological Disease
β-Amyloid (10-35), amide is composed of 26 aa (10-35 residues of the Aβ peptide) and is the primary component of the amyloid plaques of Alzheimer’s disease.

HY-P3781

*(Met(O)35)-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
(Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD).

HY-P3783

(Nle35)-Amyloid β-Protein (1-42) (ammonium)
Amyloid-β Others

(Nle35)-Amyloid β-Protein (1-42) ammonium is a peptide.

HY-P2550

*β-Amyloid* (1-40), FAM-labeled**	Amyloid-β Others	Neurological Disease
β-Amyloid (1-40), FAM-labeled is a FAM fluorescently-labelled β-Amyloid (1-40) peptide (λ_ex= 492 nm and λ_em= 518 nm).

HY-P2283

*β-Amyloid* (1-37) (human)**	Amyloid-β	Neurological Disease
β-Amyloid (1-37) (human) correlates moderately with Mini-Mental State Examination (MMSE) scores in Alzheimer disease. β-Amyloid (1-37) (human) possesses an added diagnostic value.

HY-P2562

*β-Amyloid* (1-38), mouse, rat**	Amyloid-β	Neurological Disease
β-Amyloid (1-38), mouse, rat is composed of 38 aa (1-38 residues of the Aβ peptide) and is the primary component of the amyloid plaques of Alzheimer’s disease.

HY-P0265

β-Amyloid (1-40)
Amyloid-β Neurological Disease

β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease.

HY-P1378

*β-Amyloid* (1-43)(human)**	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use.

HY-P3860

*Biotinyl-Amyloid* β-Protein (1-42) (ammonium)**	Amyloid-β	Neurological Disease
Biotinyl-Amyloid β-Protein (1-42) ammonium is a biotinylated Amyloid β-Protein (1-42) (HY-P1363). Biotinyl-Amyloid β-Protein (1-42) ammonium can be used for the research of Aβ1-42 converts to Aβ1-40 in brain.

HY-P1378A

*β-Amyloid* (1-43)(human) TFA**	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use.

HY-P1894

*β-Amyloid* Protein Precursor 770 (135-155)**	Amyloid-β	Neurological Disease
β-Amyloid Protein Precursor 770 (135-155) is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42.

HY-103538

JLK-6	Amyloid-β	Neurological Disease
JLK-6 markedly reduce the production of amyloid β-peptide (Aβ) by amyloid-β Precursor protein (APP) expressing HEK293 cells by affecting the γ-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor.

HY-P99481

Birtamimab NEOD001	Amyloid-β	Neurological Disease
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the *amyloid*. Birtamimab can be used for the research of light chain amyloidosis.

HY-W176465

BTA-2	Amyloid-β	Others
BTA-2, a benzothiazole dye, is structurally similar to thioflavin T (ThT), which exhibits an enhanced fluorescence signal when bound to amyloid fibrils. BTA-2 has distinct absorption and emission characteristics in solution and when bound to amyloid fibrils, which makes it can used for identifying amyloid fibrils using spectroscopy.

HY-P3908

*FITC-β-Ala-Amyloid* β-Protein (1-42) (ammonium)**	Amyloid-β	Neurological Disease
FITC-β-Ala-Amyloid β-Protein (1-42) ammonium is a FITC tagged Aβ1-42 monomer peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease.

HY-P99317

Solanezumab Immunoglobulin G1, anti-(human β-amyloid) (human-mouse monoclonAnti-Human Abeta Recombinant Antibody	Amyloid-β	Neurological Disease
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease.

HY-113950

Dichlorophenyl-ABA	Transthyretin (TTR)	Neurological Disease
Dichlorophenyl-ABA is an inhibitor of *transthyretin (TTR) amyloid* fibril formation, inhibiting aggregate formation in more than 80% in TTR** L55P-expressing cells.

HY-W091734

Methyl 4-iodo-L-phenylalaninate hydrochloride	Amino Acid Derivatives	Neurological Disease Cardiovascular Disease
Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease.

HY-P9967

Aducanumab BIIB037	Amyloid-β	Neurological Disease
Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.

HY-117983

RU-505	Amyloid-β	Neurological Disease
RU-505 is an effective *β-amyloid* (Aβ)-fibrinogen interaction inhibitor with IC₅₀s of 5.00 and 2.72 μM in fluorescence polarization (FP) and AlphaLISA assays, respectively. RU-505 is highly permeable to the BBB. RU-505 reduces cerebral amyloid angiopathy (CAA). RU-505 can be used for the research of Alzheimer’s disease (AD).

HY-D0333

Direct Red 80 Sirius Red	Amyloid-β	Others
Direct Red 80 (Sirius Red) is a polyazo dye used principally in staining methods for collagen and amyloid. Direct Red 80 does not release benzidine upon degradation and is safer than many traditional direct dyes.

HY-150049

γ-Secretase modulator 13	Amyloid-β	Neurological Disease
γ-Secretase modulator 13 (compound 4) is a gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC₅₀ value of 163 nM. γ-Secretase modulator 13 can be used in the study of Alzheimer's disease.

HY-122080

Memoquin	Cholinesterase (ChE) Beta-secretase Amyloid-β	Neurological Disease
Memoquin is an anti-amyloid and anti-oxidant multi-target-directed ligand. Memoquin is an orally active inhibitor of BACE-1 and AChE with IC₅₀ values of 108 and 1.55 nM, respectively. Memoquin is a cognitive enhancer that prevents the Aβ-induced neurotoxicity mediated by oxidative stress. Memoquin can be used for the research of Alzheimer’s disease (AD).

HY-150050

gamma-secretase modulator 5	Amyloid-β	Neurological Disease
gamma-secretase modulator 5 (compound 22d) is a brain-penetrant gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC₅₀ value of 60 nM. gamma-secretase modulator 5 can be used in the study of Alzheimer's disease.

HY-N8161

Kaempferol-3,7-di-O-β-glucoside Kaempferol 3,7-diglucoside	Glucosidase Cholinesterase (ChE)	Neurological Disease
Kaempferol-3,7-di-O-β-glucoside (Kaempferol 3,7-diglucoside), a flavonol, possesses enzyme inhibition property towards α-amylase, α-glucosidase and Acetylcholinesterase. Kaempferol-3,7-di-O-β-glucoside protects differentiating neuronal cells, SH-SY5Y from Amyloid β peptide-induced injury. Kaempferol-3,7-di-O-β-glucoside has the potential for Alzheimer's research.

HY-144775

AChE-IN-10	Cholinesterase (ChE)	Neurological Disease
AChE-IN-10 (Compound 24r) is a potent inhibitor of AChE (IC₅₀ = 2.4 nM). AChE-IN-10 potently inhibits AChE, reduces tau phosphorylation at S396 residue, provides neuroprotection by rescuing neuronal morphology and increasing cell viability. AChE-IN-10 is also found to reduce amyloid aggregation in the presence of AChE.

HY-148089

Eplontersen	Transthyretin (TTR)	Neurological Disease
Eplontersen is a triantennary N-acetyl galactosamine (GalNAc₃-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases.

HY-P3340

Leptin (116-130)	iGluR	Neurological Disease
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD).

HY-50882

ELN318463	γ-secretase	Neurological Disease
ELN318463 is an amyloid precursor protein (APP) selective γ-secretase inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC₅₀s of 12 nM and 656 nM for PS1 and PS2, respectively. ELN318463 is 51-fold more selective for PS1.

HY-146139

Aβ-IN-3	Amyloid-β	Neurological Disease
Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one.

HY-146140

Aβ-IN-4	Amyloid-β	Neurological Disease
Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one.

HY-50882A

ELN318463 racemate	γ-secretase	Neurological Disease
ELN318463 racemate is the racemate of ELN318463. ELN318463 is an amyloid precursor protein (APP) selective γ-secretase inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC₅₀s of 12nM and 656 nM for PS1and PS2, respectively. ELN318463 is 51-fold more selective for PS1.

HY-101861

Miridesap CPHPC; Ro63-8695; GSK2315698	Others	Neurological Disease
Miridesap is a ligand for *serum amyloid* P component (SAP) and intends to inhibit and dissociate SAP** binding to amyloid fibrils and tangles.

HY-146347

MAO-B-IN-10	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated MAO-B (monoamine oxidase-B) inhibitor, with IC₅₀ of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research.

HY-100936

Etazolate hydrochloride SQ 20009; EHT 0202 hydrochloride	Phosphodiesterase (PDE) GABA Receptor	Inflammation/Immunology Neurological Disease
Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC₅₀ of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABA_A) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloid precursor protein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects.

HY-14537

Latrepirdine dihydrochloride Dimebolin dihydrochloride	Amyloid-β Histamine Receptor Adrenergic Receptor 5-HT Receptor Autophagy	Neurological Disease Endocrinology
Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and *amyloid-β* (Aβ) secretion.

HY-111513

4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine	Amyloid-β	Neurological Disease
4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine is a potent amyloid imaging agent which binds to *Amyloid-β* (1-40) with a K_D of 1.7 nM.

HY-W010041

Scyllo-Inositol	Amyloid-β Endogenous Metabolite	Neurological Disease
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of *amyloid-β* peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model.

HY-P99022

Gantenerumab	Amyloid-β	Neurological Disease
Gantenerumab is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab can be used for Alzheimer's disease research.

HY-139516

AZD4694 Precursor AZ13040214; NAV4614	Amyloid-β	Others
AZD4694 Precursor (AZ13040214) is the precursor of [¹⁸F] AZD4694 for the synthesis of [¹⁸F] AZD4694, an amyloid-β imaging ligand with high affinity for amyloid-β plaques.

HY-124832

δ-Secretase inhibitor 11	Caspase Amyloid-β	Neurological Disease
δ-Secretase inhibitor 11 (compound 11) is an orally active, potent, BBB-penetrated, non-toxic, selective and specific δ-secretase inhibitor, with an IC₅₀ of 0.7 μM. δ-Secretase inhibitor 11 interacts with both the active site and allosteric site of δ-secretase. δ-Secretase inhibitor 11 attenuates tau and APP (amyloid precursor protein) cleavage. δ-Secretase inhibitor 11 ameliorates synaptic dysfunction and cognitive impairments in tau P301S and 5XFAD transgenic mouse models. δ-Secretase inhibitor 11 can be used for Alzheimer's disease research.

HY-14176

Compound E γ-Secretase-IN-1	γ-secretase	Cancer
Compound E is a γ-secretase inhibitor. Compound E bloks β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀s of 0.24, 0.37, 0.32 nM, respectively.

HY-147820

AY1511
Amyloid-β Neurological Disease

AY1511 is an amyloid β (Aβ) aggregation inhibitor with low cytotoxicity.
HY-17631A

Edonerpic maleate
T-817 maleate; T-817MA
Amyloid-β Neurological Disease

Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides (Aβ).

HY-147387

DSS30	CDK Amyloid-β	Inflammation/Immunology
DSS30 is a P25/CDK5 inhibitor that reduces β-amyloid (Aβ) secretion by inhibiting amyloid precursor protein lyase 1 (BACEl) phosphorylation. DSS30 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.

HY-111267

Aftin-4
Amyloid-β Neurological Disease

Aftin-4 is an Amyloid-β₄₂ (Aβ₄₂) inducer.
HY-123495

CRANAD-28
Fluorescent Dye Neurological Disease

CRANAD-28 is a robust fluorescent compound for visualization of amyloid beta plaques.

HY-103374

Phenserine (-)-Eseroline phenylcarbamate; (-)-Phenserine	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Phenserine ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces *β-amyloid* precursor protein (APP) and β-amyloid peptide (Aβ)** formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease.

HY-D0218

Thioflavin T
Basic Yellow 1
Amyloid-β Others

Thioflavin T is a cationic Benzothiazole dye that shows enhanced fluorescence upon binding to amyloid in tissue sections.

HY-14759

Aleplasinin PAZ-417	PAI-1 Amyloid-β	Neurological Disease
Aleplasinin is an orally active, potent, BBB-penetrated and selectiveSERPINE1 (PAI-1, Plasminogen activator inhibitor-1) inhibitor. Aleplasinin increases amyloid-β (Aβ) catabolism and ameliorates amyloid-related pathology. Aleplasinin improves memory deficiency. Aleplasinin can be used for Alzheimer's disease research.

HY-139324

Cu(II)GTSM	GSK-3 Amyloid-β	Neurological Disease
Cu(II)GTSM, a cell-permeable Cu-complex, significantly inhibits GSK3β. Cu(II)GTSM inhibits Amyloid-β oligomers (AβOs) and decreases tau phosphorylation. Cu(II)GTSM also decreases the abundance of Amyloid-β trimers. Cu(II)GTSM is a potential anticancer and antimicrobial agent.

HY-P0121

ReACp53
MDM-2/p53 Cancer

ReACp53 could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.

HY-137315S

TML-6-d3	NF-κB mTOR Keap1-Nrf2 Amyloid-β	Neurological Disease
TML-6-d₃ is the deuterium labeled TML-6. TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-

HY-105252A

BF 227
Amyloid-β Neurological Disease

BF 227 is a candidate for an amyloid imaging probe for PET, with a K_i of 4.3 nM for Aβ1-42 fibrils.

HY-W004287

Methyl tridecanoate	Amyloid-β Cholinesterase (ChE)	Neurological Disease
Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE).

HY-100275

MK-3328
Amyloid-β Neurological Disease

MK-3328 is a β-Amyloid PET ligand, which exhibits high binding potency with an IC₅₀ of 10.5 nM.
HY-D0236

Congo Red
Fluorescent Dye Others

Congo Red is an azo dye. Congo Red (CR) binding been used as a diagnostic test for the presence of amyloid in tissue sections.

HY-N0225

(-)-Epigallocatechin Epigallocatechin; L-Epigallocatechin	MMP Autophagy	Cancer
(-)-Epigallocatechin (Epigallocatechin) is the most abundant flavonoid in green tea, can bind to unfolded native polypeptides and prevent conversion to amyloid fibrils.

HY-P0198

Neuropeptide Y (human)	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-130244

BACE1-IN-5	Beta-secretase	Neurological Disease
BACE1-IN-5 (Compound 15) is a *β-site amyloid* precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC₅₀** of 9.1 nM, and also inhibits cellular amyloid-β (Aβ) with an IC₅₀ of 0.82 nM. BACE1-IN-5 has a medicinal chemistry that improves hERG inhibition and P-gp efflux.

HY-P0198A

Neuropeptide Y (human) (TFA)	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-100200

SMER28
Autophagy Cancer

SMER28 is a positive regulator of autophagy acting via an mTOR-independent mechanism. SMER28 prevents the accumulation of amyloid beta peptide.
HY-14562

TBPB
mAChR Neurological Disease

TBPB is an allosteric M1 mAChR agonist(EC50=289 nM) that regulates amyloid processing and produces antipsychotic-like activity in rats.

HY-137315

TML-6	Amyloid-β NF-κB mTOR Keap1-Nrf2	Neurological Disease
TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and *β-amyloid* (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-oxidative Nrf2** gene. TML-6 has the potential for Alzheimer’s disease (AD) research.

HY-126047B

(R)-(+)-Anatabine	NF-κB Amyloid-β nAChR	Inflammation/Immunology Neurological Disease
(R)-(+)-Anatabine is an less active R-enantiomer of Anatabine. Anatabine is a potent α4β2 nAChR agonist. Anatabine inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment.

HY-P99185

Bapineuzumab	Amyloid-β	Neurological Disease
Bapineuzumab is an *anti-β-amyloid* protein (APP) monoclonal antibody**. Bapineuzumab can be used for the research of Alzheimer’s disease (AD).

HY-P1729

M-2420
Fluorescent Dye Neurological Disease

M-2420 is a fluorogenic substrate containing β-secretase site of the Swedish mutation of amyloid precursor protein (APP).

HY-137131

DC-Chol hydrochloride DC-Cholesterol hydrochloride	Amyloid-β	Neurological Disease
DC-Chol hydrochloride could inhibit Aβ40 fibril formation under appropriate experimental conditions. DC-Chol hydrochloride strongly inhibits amyloidogenesis of oxidized hCT in a dose-dependent manner.

HY-N7887

Cassiaside	Beta-secretase	Inflammation/Immunology Neurological Disease
Cassiaside is a naphthopyrone glucoside, shows mixed-type inhibition against BACE1 (IC₅₀=4.45 μM; K_i=9.85 μM). Cassiaside possesses potential anti- Alzheimer's disease (AD) activity.

HY-19918A

Anatabine dicitrate	NF-κB Amyloid-β nAChR	Inflammation/Immunology Neurological Disease
Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. Anatabine dicitrate is a potent α4β2 nAChR agonist. Anatabine dicitrate inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine dicitrate has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment.

HY-N0663

Talatisamine	Potassium Channel	Neurological Disease
Talatisamine, a aconitum alkaloid, is specific K⁺ channel blocker. Talatisamine attenuates beta-amyloid oligomers induced neurotoxicity in cultured cortical neurons.

HY-N7981

Pratensein	NF-κB	Neurological Disease
Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels.

HY-B1141

Eprodisate disodium NC-503	Amyloid-β	Others
Eprodisate disodium (NC-503) is the orally available disodium salt form of Eprodisate, a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis.

HY-50883

BMS 299897	γ-secretase	Neurological Disease
BMS 299897 is a sulfonamide γ-secretase inhibitor with an IC₅₀ of 7 nM for Aβ production inhibition in HEK293 cells stably overexpressing amyloid precursor protein (APP).

HY-103240

Methoxy-X04	Amyloid-β	Others
Methoxy-X04 is a fluorescent dye that crosses the blood-brain barrier and selectively binds to beta-pleated sheets found in dense core amyloid Aβ plaques.

HY-N7368

Hibifolin	Adenosine Deaminase	Cancer Inflammation/Immunology Neurological Disease
Hibifolin, a flavonol glycoside, is a potential inhibitor of adenosine deaminase (ADA), with a K_i of 49.92 μM. Hibifolin protects neurons against beta-amyloid-induced neurotoxicity.

HY-D1494

FSB	Amyloid-β	Neurological Disease
FSB is a fluorescent dye that can be used to detect filamentous tau and to label human amyloid lesions with high sensitivity and specificity (excitation: 390 nm, emission: 520 nm).

HY-113938

AZD4694 NAV4694	Amyloid-β	Cardiovascular Disease
AZD4694 (NAV4694), a fluorinated β-amyloid (Aβ) plaque neuroimaging PET radioligand, shows high affinity for Aβ fibrils (K_d = 2.3 nM).

HY-105445

CP-113818
Acyltransferase Neurological Disease

CP-113818 is a potent cholesterol acyltransferase (ACAT) inhibitor. CP-113818 can be used for the research of Alzheimer's disease.

HY-112157

PF-06751979	Beta-secretase	Neurological Disease
PF-06751979 is a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC₅₀ of 7.3 nM in BACE1 binding assay.

HY-111514

4-(6-Bromo-2-benzothiazolyl)benzenamine	Amyloid-β	Neurological Disease
4-(6-Bromo-2-benzothiazolyl)benzenamine is a *β-amyloid* PET (positron emission tomography) tracer that can be used in the diagnosis of neurological diseases, such as Alzheimer's and Down's syndrome.

HY-W004287S

Methyl tridecanoate-d25	Amyloid-β Cholinesterase (ChE)
Methyl tridecanoate-d₂₅ is the deuterium labeled Methyl tridecanoate. Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE)[1].

HY-N2922

β-Amyrin	Amyloid-β	Neurological Disease
β-Amyrin, an ingredient of Celastrus hindsii, blocks amyloid β (Aβ)-induced long-term potentiation (LTP) impairment. β-amyrin is a promising candidate of treatment for AD.

HY-P99859

Donanemab LY3002813	Amyloid-β	Neurological Disease
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research.

HY-P2497

Exendin (5-39)	GCGR	Neurological Disease
Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats.

HY-N0044

Ginsenoside Re Ginsenoside B2; Panaxoside Re; Sanchinoside Re	Amyloid-β NF-κB JNK Endogenous Metabolite	Inflammation/Immunology Neurological Disease Cancer
Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the *β-amyloid* protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.

HY-14175

Begacestat GSI-953	γ-secretase	Neurological Disease
Begacestat (GSI-953) is a selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase (IC₅₀Aβ₄₀=15 nM) for the treatment of Alzheimer's disease.

HY-124876

SynuClean-D SC-D	α-synuclein	Neurological Disease
SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease.

HY-P3926

Amylin (8-37) (human) hIAPP (8-37)	Amylin Receptor	Metabolic Disease
Amylin (8-37) (human) (hIAPP (8-37)) is a 8-37 fragment of human islet amyloid polypeptide (IAPP). The duplex folding structure in the Amylin (8-37) (human) assembly has a hairpin structure.

HY-103470

K114	Fluorescent Dye	Others
K114, a fluorescent Congo Red analogue, binds tightly to amyloid fibrils with an EC₅₀ of 20-30 nM. K114 is an efficient detector of semen-derived enhancer of virus infection (SEVI).

HY-136480

Chrysamine G	Amyloid-β	Neurological Disease
Chrysamine G, a carboxylic acid analogue of Congo Red, can be used as a probe of amyloid deposition in Alzheimer's disease. Chrysamine G also can inhibit Aβ-induced toxicity in PC12 cells.

HY-107790

5-Methoxyflavone	DNA/RNA Synthesis	Neurological Disease
5-Methoxyflavone, belonged to Flavonoid family, is a DNA polymerase-beta inhibitor and neuroprotective agent against beta-amyloid toxicity. possess central nervous system (CNS) depressant effect mediated through the ionotropic GABA_A receptors.

HY-16659

EHT 1864	Ras	Neurological Disease Cancer
EHT 1864 is an inhibitor of Rac family small GTPases. EHT 1864 directly binds and impairs the ability of this small GTPase to engage critical downstream effectors required for growth transformation. The K_d values are 40, 50, 60, and 230 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. EHT 1864 also potently inhibits other Rac-dependent transformation processes, Tiam1- and Ras-mediated growth transformation. EHT 1864 prevents Aβ 40 and Aβ 42 production in vivo. EHT 1864 dependently suppresses the release of migrasomes from podocytes induced by LPS, PAN, or HG.

HY-P99689

Lecanemab BAN-2401	Amyloid-β	Neurological Disease
Lecanemab (BAN-2401) is an IgG1 anti-soluble aggregated amyloid beta (Aβ) monoclonal antibody. Lecanemab shows activity across oligomers, protofibrils and insoluble fibrils. Lecanemab can be used for the research of Alzheimer's Disease.

HY-111263

NIAD-4	Amyloid-β	Neurological Disease
NIAD-4 is a fluorophore for optical imaging of *amyloid-β* (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (K_i) of 10 nM.

HY-D1443

BSB (trans,trans)-1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene	Amyloid-β	Others
BSB is a Congo red-derived fluorescent probe. BSB binds not only to extracellular amyloid β protein, but also many intracellular lesions composed of abnormal tau and synuclein proteins. BSB acts as a prototype imaging agent for Alzheimer's disease.

HY-N2319

Dihydroergocristine mesylate DHEC mesylate	Amyloid-β	Neurological Disease
Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease *amyloid-β* peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively.

HY-124322

NB-360	Beta-secretase	Inflammation/Immunology Neurological Disease
NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC₅₀: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E.

HY-N1255

Scoulerine (-)-Scoulerine; Discretamine	Microtubule/Tubulin Beta-secretase Apoptosis	Cancer
Scoulerine ((-)-Scoulerine), an isoquinoline alkaloid, is a potent antimitotic compound. Scoulerine is also an inhibitor of BACE1 (ß-site amyloid precursor protein cleaving enzyme 1). Scoulerine inhibits proliferation, arrests cell cycle, and induces apoptosis in cancer cells.

HY-P99216

Ponezumab PF-04360365; RN 1219	EGFR	Neurological Disease
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease.

HY-U00287

BACE-IN-1	Beta-secretase	Neurological Disease
BACE-IN-1 (Compound 13) is a substituted lmidazo[1 ,2-a]pyridine derivative which can inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease.

HY-114174

Fmoc-Ala-Glu-Asn-Lys-NH2	Amyloid-β	Neurological Disease
Fmoc-Ala-Glu-Asn-Lys-NH2 is a selective asparagine endopeptidase (AEP) inhibitor peptide and suppresses amyloid precursor protein (APP) cleavage. AEP, a pH-controlled cysteine proteinase, is activated during ageing and mediates APP proteolytic processing.

HY-P0198B

[D-Arg25]-Neuropeptide Y (human)	Neuropeptide Y Receptor	Metabolic Disease Neurological Disease
[D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY) is a Y₁ receptor selective agonist. Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-N2898

Artanin	Cholinesterase (ChE)	Neurological Disease
Artanin is a coumarin, has biological activities related to Alzheimer’s disease. Artanin exerts function including AChE inhibitory and AChE- and self-induced amyloid beta (Aβ) aggregation inhibitory activities, with IC₅₀s of 51 μM, 98 μM, and 124 μM, respectively.

HY-128849

Eprodisate	Others	Inflammation/Immunology
Eprodisate is a new compound designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues. Eprodisate slow the progression of AA amyloidosis-related renal disease and has possible applicability to other types of amyloidosis.

HY-103373

PE154	Cholinesterase (ChE)	Neurological Disease
PE154 (Compound 13) is a potent fluorescent inhibitor of human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) (IC₅₀s=280 pM and 16 nM, respectively). PE154 can label β-amyloid plaques in histochemical analysis.

HY-128774

AM-6494	Beta-secretase	Neurological Disease
AM-6494 is a potent and orally active BACE1 (efficacious β-site amyloid precursor protein cleaving enzyme 1) inhibitor (IC₅₀=0.4 nM) with in vivo selectivity over BACE2 (IC₅₀=18.6 nM).

HY-N6904

Crocetin β-Crocetin	Amyloid-β	Inflammation/Immunology Neurological Disease
Crocetin (β-Crocetin), isolated from Crocus sativus, possesses anti-inflammatory, neuroprotective and antioxidant activity. Crocetin promotes clearance of *amyloid-β* by inducing autophagy via the STK11/LKB1-mediated AMPK pathway.

HY-100604

JNJ-40418677	γ-secretase Amyloid-β	Neurological Disease
JNJ-40418677 is an orally active modulator of γ-secretase, can cross the blood-brain barrier. JNJ-40418677 inhibits Aβ42 and NS2B-NS3 protease, with IC₅₀s of 200 nM and 3.9 μM, respectively. JNJ-40418677 displays good biological tolerance, can be use for Alzheimer’s disease research.

HY-119689

Umibecestat CNP520	Beta-secretase	Neurological Disease
Umibecestat (CNP520) is a *beta-site amyloid* precursor protein cleaving enzyme-1 (BACE-1) inhibitor with IC₅₀**s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively. Umibecestat can be used for the research of alzheimer's disease.

HY-111379

EHT 5372	DYRK CDK GSK-3	Cancer Metabolic Disease Neurological Disease
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively.

HY-B1794

Thiethylperazine	Dopamine Receptor Histamine Receptor Bacterial Amyloid-β	Infection Neurological Disease
Thiethylperazine, a phenothiazine derivate, is an orally active and potent dopamine D2-receptor and histamine H1-receptor antagonist. Thiethylperazine is also a selective ABCC1activator that reduces amyloid-β (Aβ) load in mice. Thiethylperazine has anti-emetic, antipsychotic and antimicrobial effects.

HY-10009

Semagacestat LY450139	γ-secretase Amyloid-β Notch	Neurological Disease
Semagacestat is a γ-secretase inhibitor, inhibits *β-amyloid* (Aβ42), Aβ38 and Aβ40 with IC₅₀s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC₅₀ of 14.1 nM. Semagacestat can be used for the research of alzheimer's disease.

HY-N0249

Saikosaponin C	Amyloid-β	Neurological Disease
Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression.

HY-109052

Atabecestat JNJ-54861911	Beta-secretase	Neurological Disease
Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active *β-site amyloid* precursor protein cleaving enzyme 1 (BACE1)** inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment.

HY-N1280

Semilicoisoflavone B	Amyloid-β	Neurological Disease
Semilicoisoflavone B, an isoflavone, mainly derived from Glycyrrhiza uralensis Fisch.. Semilicoisoflavone B reduces amyloid β (Aβ) secretion by inhibiting β-secretase-1 (BACE1) expression and activity. Semilicoisoflavone B decreases BACE1 expression mainly through increasing PPARγ expression and inhibiting STAT3 phosphorylation.

HY-139973

OAB-14	Amyloid-β	Neurological Disease
OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice.

HY-B1794A

Thiethylperazine dimaleate	Dopamine Receptor Histamine Receptor Bacterial Amyloid-β	Infection Neurological Disease
Thiethylperazine dimaleate, a phenothiazine derivate, is an orally active and potent dopamine D2-receptor and histamine H1-receptor antagonist. Thiethylperazine dimaleate is also a selective ABCC1activator that reduces amyloid-β (Aβ) load in mice. Thiethylperazine dimaleate has anti-emetic, antipsychotic and antimicrobial effects.

HY-151962

JNK3 inhibitor-5	JNK Apoptosis GSK-3 p38 MAPK	Neurological Disease
JNK3 inhibitor-5 (Compound 22b) is a potent and selective JNK3 inhibitor with an IC₅₀ of 0.379 nM. JNK3 inhibitor-5 effectively protects the neuronal cells against amyloid beta-induced apoptosis. JNK3 inhibitor-5 has a high cell permeability and is predicted as BBB permeable.

HY-N0061

Ethyl ferulate	Reactive Oxygen Species	Neurological Disease
Ethyl ferulate, a naturally lipophilic derivative of ferulic acid originally derived from Rhizoma Chuanxiong, induces heme oxygenase-1 (HO-1) and protects rat neurons against oxidative stress. Ethyl ferulate also protects neurons against amyloid β peptide (1-42)-induced oxidative stress and neurotoxicity.

HY-151554

SQ-3	Amyloid-β	Others
SQ-3 is a quinoline analogue, displays moderate selectivity for α-syn aggregates (K_i=39.3 nM) over β-amyloid (Aβ) aggregates (K_i=230 nM). [¹⁸F]SQ3 has basic properties as a lead compound for the development of a useful α-syn imaging probe.

HY-117259

Valiltramiprosate ALZ-801	Amyloid-β	Neurological Disease
ALZ-801 is a potent and orally available small-molecule *β-amyloid* (Aβ)** anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease.

HY-P1119

WRW4	Formyl Peptide Receptor (FPR)	Neurological Disease
WRW4, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC₅₀ of 0.23 μM. WRW4 specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide.

HY-103442

CGP52411 DAPH	EGFR Amyloid-β	Cancer Neurological Disease
CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC₅₀ of 0.3 μM. CGP52411 blocks the toxic influx of Ca²⁺ ions into neuronal cells, and dramatic inhibits and reverses the formation of *β-amyloid* (Aβ42)** fibril aggregates associated with Alzheimer's disease.

HY-131068

BACE-1 inhibitor 2
Beta-secretase Neurological Disease

BACE-1 inhibitor 2 is a potent and CNS permeable BACE-1 inhibitor with an IC₅₀ of 1.5 nM in BACE-1 enzymatic assay.

HY-B0116

Stavudine d4T	Reverse Transcriptase HIV Nucleoside Antimetabolite/Analog NOD-like Receptor (NLR) Autophagy Apoptosis	Infection
Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis.

HY-B0116A

Stavudine sodium d4T sodium	Reverse Transcriptase HIV Nucleoside Antimetabolite/Analog NOD-like Receptor (NLR) Autophagy Apoptosis	Infection
Stavudine (d4T) sodium is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine sodium has activity against HIV-1 and HIV-2. Stavudine sodium also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine sodium reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine sodium induces apoptosis.

HY-P1119A

WRW4 TFA	Formyl Peptide Receptor (FPR)	Neurological Disease
WRW4 TFA, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC₅₀ of 0.23 μM. WRW4 TFA specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide.

HY-112636

Astrophloxine	Amyloid-β Others	Others
Astrophloxine is a fluorescent imaging probe capable of targeting antiparallel dimers. Astrophloxine can be used to detect aggregated Aβ in brain tissue and cerebrospinal fluid samples of Alzheimer's disease (AD) mice.

HY-10016

E 2012	γ-secretase	Neurological Disease
E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat.

HY-N6640

2-O-Acetyl-20-hydroxyecdysone 20-Hydroxyeedysone 2-acetate	Amyloid-β	Neurological Disease
2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β₄₂ (Aβ₄₂)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils.

HY-D1684

DCDAPH	Amyloid-β	Neurological Disease
DCDAPH (Compound 2c) is a novel smart NIRF probe for detection of *β-amyloid* (Aβ) plaques (λ_ex/λ_em=597/665 nm in PBS). DCDAPH shows high affinity for Aβ aggregates (K_i=37 nM, K_d=27 nM). DCDAPH shows good blood brain barrier permeation and can meet most of the requirements for the detection of Aβ plaques both in vitro and in vivo.

HY-13027

DAPT GSI-IX	γ-secretase Amyloid-β Autophagy Notch Apoptosis	Cancer Inflammation/Immunology Neurological Disease
DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC₅₀s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ₄₂, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment.

HY-B0116S

Stavudine-d4	Reverse Transcriptase HIV Nucleoside Antimetabolite/Analog NOD-like Receptor (NLR) Autophagy Apoptosis	Infection
Stavudine-d₄ is the deuterium labeled Stavudine. Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis[1][2][3][4].

HY-146142

AChE/BuChE-IN-2	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/BuChE-IN-2 (Compound 5f) is an orally active AChE and BuChE inhibitor with IC₅₀ values of 0.72 μM and 0.16 μM, respectively. AChE/BuChE-IN-2 shows a non-competitive inhibition with AChE and shows potent self-induced *β-amyloid* (Aβ) aggregation inhibition with an IC₅₀** of 62.52 μM. AChE/BuChE-IN-2 can cross the BBB.

HY-146151

γ-Secretase modulator 12	γ-secretase Amyloid-β	Neurological Disease
γ-Secretase modulator 12 (Compound 1a) is a γ-secretase modulator that can selectively decrease amyloid-β42 (Aβ42) levels (IC₅₀ of 0.39 µM). γ-Secretase modulator 12 can be used for Alzheimer’s disease research. γ-Secretase modulator 12 has a good brain/plasma ratio (Kp, brain = 0.72) in mice.

HY-13240

LY2886721	Beta-secretase	Neurological Disease
LY2886721 is a potent, selective and orally active *beta-site amyloid* precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC₅₀ of 20.3 nM for recombinant human BACE1. LY2886721 is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC₅₀** of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment.

HY-17447A

Tranylcypromine hydrochloride SKF 385 hydrochloride	Monoamine Oxidase	Neurological Disease
Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC₅₀s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression.

HY-146399

AChE/BChE-IN-9	Cholinesterase (ChE) ROS Kinase	Neurological Disease
AChE/BChE-IN-9 (Compound 7a) is a potent, orally active AChE and BChE inhibitor with IC₅₀ values of 5.74 μM and 14.05 μM against hAChE and eqBChE, respectively. AChE/BChE-IN-9 is also an efficacious antioxidant with an IC₅₀ of 57.35 μM. AChE/BChE-IN-9 is able to chelate iron and modulates aggregation of amyloid β_{1-42. AChE-IN-16 can cross the BBB}.

HY-120597

SAK3	Calcium Channel	Neurological Disease
SAK3 is a potent T-type voltage-gated Ca²⁺ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca²⁺ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice. SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity.

HY-116753

(-)Clausenamide	Amyloid-β Tau Protein	Neurological Disease
(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits *β-amyloid* (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ_25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD).

HY-152110

AChE/MAO-IN-2	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Dual AChE-MAO B-IN-5, indanone derivative, is a potent dual AChE/MAO-B inhibitior with IC₅₀ values of 0.0224, 0.0412, and 0.1116 μM for AChE, MAO-B and MAO-A, respectively. Dual AChE-MAO B-IN-5 has antioxidant activity and prevents β-amyloid plaque aggregation. Dual AChE-MAO B-IN-5 can be used for Alzheimer’s disease (AD) research.

HY-12452

DPN Diarylpropionitrile	Estrogen Receptor/ERR Apoptosis Autophagy	Neurological Disease
DPN (Diarylpropionitrile) is a non-steroidal estrogen receptor β (ERβ) selective ligand, with an EC₅₀ of 0.85 nM. DPN has neuroprotective effects in a number of neurological diseases.

HY-113509

Lipoxin A4 LXA4	Interleukin Related Endogenous Metabolite	Inflammation/Immunology
Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC₅₀ value of 25.74 nM.

HY-101855

Anle138b	Amyloid-β	Neurological Disease
Anle138b, an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Anle138b strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Anle138b has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology.

HY-P3528

GPR	Caspase Apoptosis	Neurological Disease
GPR is a three amino acid peptide. GPR can rescue cultured rat hippocampal neurons from Aβ-induced neuronal death by inhibiting caspase-3/p53 dependent apoptosis. GPR can be used for the research of Alzheimer's disease (AD).

HY-14442

ML 10302 hydrochloride	5-HT Receptor	Metabolic Disease Neurological Disease
ML 10302 hydrochloride is a potent and selective 5-HT₄ receptor agonist, with an EC₅₀ of 4 nM. ML 10302 hydrochloride displays more than 680-fold selectivity over 5-HT₃ receptor in binding assay.

HY-146314

MAO-B-IN-9	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects.

HY-113509S

Lipoxin A4-d5 LXA4-d₅	Interleukin Related Endogenous Metabolite	Inflammation/Immunology
Lipoxin A4-d₅ is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].

HY-136742

BACE2-IN-1	Beta-secretase	Metabolic Disease
BACE2-IN-1 (compound 3l) is a highly selective BACE2 inhibitor with a Kⁱ value of 1.6 nM. BACE2 inhibitors can be used to research of Type 2 Diabetes.

HY-19369

L-685458 L-685,458	γ-secretase Apoptosis	Neurological Disease Cancer
L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC₅₀ of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC₅₀s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers.

HY-152114

AChE/BChE/MAO-B-IN-4	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
AChE/BChE/MAO-B-IN-4, an indan-1-one derivative, is a potent MAO-B inhibitor with an IC₅₀ of 0.0393 μM for human MAO-B. AChE/BChE/MAO-B-IN-4 is a potent AChE and BChE enzyme inhibitor, with IC₅₀s of 0.0458 μM and 0.075 μM for human AChE and BChE enzyme, respectively. AChE/BChE/MAO-B-IN-4 shows significant antioxidant activity and prevent β-amyloid plaque aggregation. AChE/BChE/MAO-B-IN-4 has the potential for Alzheimer's disease (AD) research.

HY-N0373

Licochalcone B	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Neurological Disease
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction.

HY-146483

Anti-Aβ agent 1A	Amyloid-β	Inflammation/Immunology Neurological Disease
Anti-Aβ agent 1A (compound M15) has potent activity against *amyloid-β*. Anti-Aβ agent 1A possesses can significantly inhibit LPS-induced levels of IL-1β, IL-6 and TNF-α, and reduces the apoptosis of SH-SY5Y induced by H₂O₂ through mitochondria pathway. Anti-Aβ agent 1A possesses antioxidant, anti-inflammatory, anti-Aβ toxicity and neuroprotective activities. Anti-Aβ agent 1A can be used for researching Alzheimer’s disease (AD).

HY-136813

Multitarget AD inhibitor-1	Beta-secretase Amyloid-β Cholinesterase (ChE)	Neurological Disease
Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC₅₀s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC_50hBACE-1=41.60 μM), amyloid β aggregation (IC_50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research.

HY-16561

Resveratrol trans-Resveratrol; SRT501	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Cancer Infection Inflammation/Immunology
Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, *β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.

HY-16561S1

Resveratrol-13C6 trans-Resveratrol-¹³C₆; SRT501-¹³C₆	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Cancer Infection Inflammation/Immunology
Resveratrol-¹³C₆ is the ¹³C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-103241

Ro 90-7501	Amyloid-β ATM/ATR Phosphatase Apoptosis	Cancer Neurological Disease
Ro 90-7501 is an amyloid β₄₂ (Aβ₄₂) fibril assembly inhibitor that reduces Aβ₄₂-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response. Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner. Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells.

HY-16561S

Resveratrol-d4 trans-Resveratrol-d₄; SRT501-d₄	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Cancer Infection Inflammation/Immunology
Resveratrol-d₄ is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-N8376

Fustin (±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone	Amyloid-β mAChR Cholinesterase (ChE)	Neurological Disease
Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) is a potent amyloid β (Aβ) inhibitor. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases the expression of acetylcholine (ACh) levels, choline acetyltransferase (ChAT) activity, and ChAT gene induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) decreases in acetyl cholinesterase (AChE) activity and AChE gene expression induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases muscarinic M1 receptor gene expression and muscarinic M1 receptor binding activity. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) can be used for Alzheimer's disease research.

HY-P0014

Liraglutide
GCGR Metabolic Disease

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
HY-P0014S

Liraglutide-d8 triTFA
Isotope-Labeled Compounds Others

Liraglutide-d₈ (triTFA) is the deuterium labeled Liraglutide (HY-P0014)[1].

Cat. No.	Product Name

HY-L069

Anti-Alzheimer's Disease Compound Library

1138 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 1138 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

HY-L086

Neurodegenerative Disease-related Compound Library

1785 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 1785 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Cat. No.	Product Name	Type

HY-D0218

Thioflavin T
Basic Yellow 1
Dyes

Thioflavin T is a cationic Benzothiazole dye that shows enhanced fluorescence upon binding to amyloid in tissue sections.
HY-D0236

Congo Red
Dyes

Congo Red is an azo dye. Congo Red (CR) binding been used as a diagnostic test for the presence of amyloid in tissue sections.
HY-103240

Methoxy-X04
Dyes

Methoxy-X04 is a fluorescent dye that crosses the blood-brain barrier and selectively binds to beta-pleated sheets found in dense core amyloid Aβ plaques.

HY-D1494

FSB	Fluorescent Dyes/Probes
FSB is a fluorescent dye that can be used to detect filamentous tau and to label human amyloid lesions with high sensitivity and specificity (excitation: 390 nm, emission: 520 nm).

HY-103470

K114	Fluorescent Dyes/Probes
K114, a fluorescent Congo Red analogue, binds tightly to amyloid fibrils with an EC₅₀ of 20-30 nM. K114 is an efficient detector of semen-derived enhancer of virus infection (SEVI).

HY-111263

NIAD-4	Fluorescent Dyes/Probes
NIAD-4 is a fluorophore for optical imaging of *amyloid-β* (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (K_i) of 10 nM.

HY-103373

PE154	Fluorescent Dyes/Probes
PE154 (Compound 13) is a potent fluorescent inhibitor of human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) (IC₅₀s=280 pM and 16 nM, respectively). PE154 can label β-amyloid plaques in histochemical analysis.

HY-D1684

DCDAPH	Fluorescent Dyes/Probes
DCDAPH (Compound 2c) is a novel smart NIRF probe for detection of *β-amyloid* (Aβ) plaques (λ_ex/λ_em=597/665 nm in PBS). DCDAPH shows high affinity for Aβ aggregates (K_i=37 nM, K_d=27 nM). DCDAPH shows good blood brain barrier permeation and can meet most of the requirements for the detection of Aβ plaques both in vitro and in vivo.

Cat. No.	Product Name	Target	Research Area

HY-P1474

*β-Amyloid* (22-35)** amyloid β-Protein (22-35)	Amyloid-β	Neurological Disease
β-Amyloid 22-35 (Amyloid β-Protein 22-35), the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution).

HY-P1474A

*β-Amyloid* (22-35) (TFA)** amyloid β-Protein (22-35) (TFA)	Amyloid-β	Neurological Disease
β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution).

HY-P3779

Amyloid 17-42 Aβ(17-42)	Apoptosis	Neurological Disease
Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of *the amyloid* precursor protein (APP)*. Amyloid* 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway.

HY-P1046

*β-Amyloid* (1-15)** amyloid β-Protein (1-15)	Amyloid-β	Neurological Disease
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1468

*β-Amyloid* (1-28)** amyloid β-Protein (1-28)	Amyloid-β	Neurological Disease
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1466

*β-Amyloid* (1-16)** amyloid β-Protein (1-16)	Amyloid-β	Neurological Disease
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1522

β-Amyloid (29-40)
amyloid beta-protein(29-40)
Amyloid-β Neurological Disease

β-Amyloid (29-40) is a fragment of Amyloid-β peptide.

HY-P1051

*β-Amyloid* (12-28)** amyloid β-Protein (12-28)	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research.

HY-P0128

*β-Amyloid* (25-35)** amyloid beta-peptide (25-35); Aβ25-35; β-amyloid peptide (25-35)	Amyloid-β	Neurological Disease
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.

HY-P1362

*β-Amyloid* (42-1), human** amyloid β Peptide (42-1)(human)	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

HY-P1051A

*β-Amyloid* (12-28) (TFA)** amyloid β-Protein (12-28) (TFA); amyloid Beta-Peptide (12-28) (human) TFA; β-amyloid protein fragment(12-28) TFA	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (TFA) (Amyloid β-Protein (12-28) (TFA)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) (TFA) shows aggregation properties. β-Amyloid (12-28) (TFA) has the potential for Alzheimer’s disease research.

HY-P1362A

*β-Amyloid* (42-1), human TFA** amyloid β Peptide (42-1)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

HY-P3793

Amyloid β-Protein (33-42) (TFA)	Amyloid-β	Neurological Disease
Amyloid β-Protein (33-42) TFA is the residues 33-42 fragment of the β-amyloid protein. Amyloid β-Protein (33-42) TFA inhibits Aβ42-induced toxicity.

HY-P0265AS

*β-Amyloid-15N (1-40) (TFA)* amyloid Beta-Peptide-¹⁵N (1-40) (human) (TFA); amyloid β-Peptide-15N (1-40) (human) (TFA)	Amyloid-β	Neurological Disease
β-Amyloid- 15N (1-40) (TFA) is the ¹⁵N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease[1].

HY-P1363

*β-Amyloid* (1-42), human TFA** amyloid β-Peptide (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

HY-P1363S

*β-Amyloid-15N (1-42), human TFA* amyloid β-Peptide-¹⁵N (1-42) (human) (TFA)	Amyloid-β	Neurological Disease
β-Amyloid- 15N (1-42), human (TFA) is the ¹⁵N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease[1].

HY-P0265A

*β-Amyloid* (1-40) (TFA)** amyloid Beta-Peptide (1-40) (human) TFA; amyloid β-Peptide (1-40) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-40) TFA is a primary protein in plaques found in the brains of patients with Alzheimer's disease.

HY-P1388

*β-Amyloid* (1-42), (rat/mouse)** amyloid β-peptide (1-42) (rat/mouse)	Amyloid-β	Neurological Disease
β-Amyloid (1-42), (rat/mouse) is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.

HY-P1388A

*β-Amyloid* (1-42), (rat/mouse) (TFA)** amyloid β-peptide (1-42) (rat/mouse) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42), (rat/mouse) TFA is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.

HY-P3858

*(D-Asp1)-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
(D-Asp1)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease.

HY-P3909

*Biotinyl-Ahx-Amyloid* β-Protein (1-42) (ammonium)**	Amyloid-β	Neurological Disease
Biotinyl-Ahx-Amyloid β-Protein (1-42) ammonium is a N-terminally biotin-labeled Amyloid β-Protein (1-42). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease.

HY-P3782

(Met(O2)35)-Amyloid β-Protein (1-42)
Amyloid-β Others

(Met(O2)35)-Amyloid β-Protein (1-42) is a peptide.

HY-P3859

*Cys-Gly-Lys-Arg-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) can be used in research of Alzheimer's disease.

HY-P3780

*Cys-Gly-Lys-Lys-Gly-Amyloid* β-Protein (36-42)**	Amyloid-β	Neurological Disease
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment.

HY-P1521

β-Amyloid (15-21)
Beta-amyloid (15-21)
Amyloid-β Neurological Disease

β-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.
HY-P1880

β-Amyloid (12-20)
Amyloid-β Neurological Disease

β-Amyloid (12-20) is a peptide fragment of β-Amyloid.
HY-P1891

β-Amyloid (22-40)
Amyloid-β Neurological Disease

β-Amyloid (22-40) is a peptide fragment of β-Amyloid.
HY-P1879

β-Amyloid (18-28)
Amyloid-β Neurological Disease

β-Amyloid (18-28) is a peptide fragment of β-Amyloid.
HY-P1893

β-Amyloid (11-22)
Amyloid-β Neurological Disease

β-Amyloid (11-22) is a peptide fragment of β-Amyloid.

HY-P2551

*Biotin-β-Amyloid* (17-40)**	Amyloid-β	Neurological Disease
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-ß-(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP).

HY-P1867

β-Amyloid (1-34)
Amyloid-β Neurological Disease

β-Amyloid (1-34) is a β-Amyloid peptide consists of 34 amino acid.
HY-P1895

β-Amyloid (33-40)
Amyloid-β Neurological Disease

β-Amyloid (33-40) is a peptide consisting of amino acid of 33 to 40 of beta amyloid protein.
HY-P1903

β-Amyloid (35-42)
Amyloid-β Neurological Disease

β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.
HY-P1898

β-Amyloid (13-27)
Amyloid-β Neurological Disease

β-Amyloid (13-27) is a peptide consisting of amino acid of 13 to 27 of beta amyloid protein.

HY-P1854

*β-Amyloid* (1-9)**	Amyloid-β	Neurological Disease
β-Amyloid (1-9), an N-terminal fragment of beta amyloid, consists of amino acid residues 1 to 9. β-Amyloid (1-9) contains a B cell epitope, but it does not include T cell epitopes. Omission of residues 1 to 9 from the full-length Alzheimer'sβ-Amyloid peptide 1 to 40 does not prevent the peptide from forming amyloid fibrils or eliminate fibril polymorphism .

HY-P1510

β-Amyloid (1-11)
Amyloid-β Neurological Disease

β-Amyloid (1-11) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.
HY-P1517

β-Amyloid (31-35)
Amyloid-β Neurological Disease

β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.
HY-P1850

β-Amyloid (1-20)
Amyloid-β Neurological Disease

β-Amyloid (1-20) consists of amino acids 1 to 20 of beta amyloid protein.
HY-P2549

Biotin-β-Amyloid (1-40)
Fluorescent Dye Neurological Disease

Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-ß-(1-40) peptide.
HY-P1053

β-Amyloid (10-20)
Amyloid-β Neurological Disease

β-Amyloid (10-20) is a fragment of Amyloid-β peptide and maybe used in the research of neurological disease.
HY-P1772

β-Amyloid (1-17)
Amyloid-β Neurological Disease

β-Amyloid (1-17) is a peptide of β-Amyloid, stabilizes the fibres and plays a role in Aβ fibre formation.

HY-P3845

*(Gly22)-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease. Mutation of Glu22 to Gly22 in Aβ can increase aggregation.

HY-P1524

β-Amyloid (1-14),mouse,rat
Amyloid-β Neurological Disease

β-Amyloid (1-14),mouse,rat is a 1 to 14 fragment of Amyloid-β peptide.

HY-P3846

*(Glu20)-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease.

HY-P1387

*β-Amyloid* (1-40) (rat)**	Amyloid-β Apoptosis	Neurological Disease
β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases ⁴⁵Ca²⁺ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease.

HY-P1787

*β-Amyloid* (4-10)**	Amyloid-β	Neurological Disease
β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model.

HY-P1567

*β-Amyloid* (10-35), amide**	Amyloid-β	Neurological Disease
β-Amyloid (10-35), amide is composed of 26 aa (10-35 residues of the Aβ peptide) and is the primary component of the amyloid plaques of Alzheimer’s disease.

HY-P3781

*(Met(O)35)-Amyloid* β-Protein (1-42)**	Amyloid-β	Neurological Disease
(Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD).

HY-P3783

(Nle35)-Amyloid β-Protein (1-42) (ammonium)
Amyloid-β Others

(Nle35)-Amyloid β-Protein (1-42) ammonium is a peptide.

HY-P2550

*β-Amyloid* (1-40), FAM-labeled**	Amyloid-β Peptides	Neurological Disease
β-Amyloid (1-40), FAM-labeled is a FAM fluorescently-labelled β-Amyloid (1-40) peptide (λ_ex= 492 nm and λ_em= 518 nm).

HY-P2283

*β-Amyloid* (1-37) (human)**	Amyloid-β	Neurological Disease
β-Amyloid (1-37) (human) correlates moderately with Mini-Mental State Examination (MMSE) scores in Alzheimer disease. β-Amyloid (1-37) (human) possesses an added diagnostic value.

HY-P2562

*β-Amyloid* (1-38), mouse, rat**	Amyloid-β	Neurological Disease
β-Amyloid (1-38), mouse, rat is composed of 38 aa (1-38 residues of the Aβ peptide) and is the primary component of the amyloid plaques of Alzheimer’s disease.

HY-P0265

β-Amyloid (1-40)
Amyloid-β Neurological Disease

β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease.

HY-P1378

*β-Amyloid* (1-43)(human)**	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use.

HY-P3860

*Biotinyl-Amyloid* β-Protein (1-42) (ammonium)**	Amyloid-β	Neurological Disease
Biotinyl-Amyloid β-Protein (1-42) ammonium is a biotinylated Amyloid β-Protein (1-42) (HY-P1363). Biotinyl-Amyloid β-Protein (1-42) ammonium can be used for the research of Aβ1-42 converts to Aβ1-40 in brain.

HY-P1378A

*β-Amyloid* (1-43)(human) TFA**	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use.

HY-P1894

*β-Amyloid* Protein Precursor 770 (135-155)**	Amyloid-β	Neurological Disease
β-Amyloid Protein Precursor 770 (135-155) is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42.

HY-P3908

*FITC-β-Ala-Amyloid* β-Protein (1-42) (ammonium)**	Amyloid-β	Neurological Disease
FITC-β-Ala-Amyloid β-Protein (1-42) ammonium is a FITC tagged Aβ1-42 monomer peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease.

HY-W091734

Methyl 4-iodo-L-phenylalaninate hydrochloride	Amino Acid Derivatives	Neurological Disease Cardiovascular Disease
Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease.

HY-P3340

Leptin (116-130)	iGluR	Neurological Disease
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD).

HY-P0121

ReACp53
MDM-2/p53 Cancer

ReACp53 could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.

HY-P0198

Neuropeptide Y (human)	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-P0198A

Neuropeptide Y (human) (TFA)	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-P1729

M-2420
Fluorescent Dye Neurological Disease

M-2420 is a fluorogenic substrate containing β-secretase site of the Swedish mutation of amyloid precursor protein (APP).

HY-P2497

Exendin (5-39)	GCGR	Neurological Disease
Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats.

HY-P3926

Amylin (8-37) (human) hIAPP (8-37)	Amylin Receptor	Metabolic Disease
Amylin (8-37) (human) (hIAPP (8-37)) is a 8-37 fragment of human islet amyloid polypeptide (IAPP). The duplex folding structure in the Amylin (8-37) (human) assembly has a hairpin structure.

HY-114174

Fmoc-Ala-Glu-Asn-Lys-NH2	Amyloid-β	Neurological Disease
Fmoc-Ala-Glu-Asn-Lys-NH2 is a selective asparagine endopeptidase (AEP) inhibitor peptide and suppresses amyloid precursor protein (APP) cleavage. AEP, a pH-controlled cysteine proteinase, is activated during ageing and mediates APP proteolytic processing.

HY-P0198B

[D-Arg25]-Neuropeptide Y (human)	Neuropeptide Y Receptor	Metabolic Disease Neurological Disease
[D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY) is a Y₁ receptor selective agonist. Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-P2632A

RAD16-I hydrochloride	Peptides	Neurological Disease
RAD16-I hydrochloride, a soft nanofibrous self-assembling peptide, is a suitable microenvironment for human mesenchymal stem cells’ (hMSC) proliferation and differentiation into chondrocytes. RAD16-I is a well-studied ionic complementary peptide was used as a model to check potential amyloid-like staining properties of SAPNFs.

HY-P2632

RAD16-I	Peptides	Neurological Disease
RAD16-I, a soft nanofibrous self-assembling peptide, is a suitable microenvironment for human mesenchymal stem cells’ (hMSC) proliferation and differentiation into chondrocytes. RAD16-I is a well-studied ionic complementary peptide was used as a model to check potential amyloid-like staining properties of SAPNFs.

HY-P1119

WRW4	Formyl Peptide Receptor (FPR)	Neurological Disease
WRW4, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC₅₀ of 0.23 μM. WRW4 specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide.

HY-P1119A

WRW4 TFA	Formyl Peptide Receptor (FPR)	Neurological Disease
WRW4 TFA, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC₅₀ of 0.23 μM. WRW4 TFA specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide.

HY-P3528

GPR	Caspase Apoptosis	Neurological Disease
GPR is a three amino acid peptide. GPR can rescue cultured rat hippocampal neurons from Aβ-induced neuronal death by inhibiting caspase-3/p53 dependent apoptosis. GPR can be used for the research of Alzheimer's disease (AD).

HY-P0014

Liraglutide
GCGR Metabolic Disease

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

Cat. No.	Product Name	Target	Research Area

HY-P99358

Dezamizumab GSK 2398852; Anti-Serum amyloid P/SAP Reference Antibody (dezamizumab)	Inhibitory Antibodies	Inflammation/Immunology
Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 *anti-serum amyloid* P component (SAP)** antibody, with potential anti-amyloid activity. Dezamizumab triggers immunotherapeutic clearance of amyloid. Dezamizumab can be used in research of Amyloid light-chain (AL) amyloidosis.

HY-P99481

Birtamimab NEOD001	Amyloid-β	Neurological Disease
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the *amyloid*. Birtamimab can be used for the research of light chain amyloidosis.

HY-P99317

Solanezumab Immunoglobulin G1, anti-(human β-amyloid) (human-mouse monoclonAnti-Human Abeta Recombinant Antibody	Amyloid-β	Neurological Disease
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease.

HY-P99504

Zinpentraxin alfa PRM-151; Pentraxin-2; Serum amyloid P-component	Inhibitory Antibodies	Cardiovascular Disease
Zinpentraxin alfa (PRM-151) is a recombinant human pentraxin-2, also known as serum amyloid hSAP, a highly conserved serum protein and soluble pattern recognition receptor (PRR) of the innate immune system that regulates monocyte activation and differentiation. Zinpentraxin alfa inhibits the differentiation of circulating monocytes into fibroblasts and pro-fibroblastic macrophages and suppresses myofibroblast production.

HY-P9967

Aducanumab BIIB037	Amyloid-β	Neurological Disease
Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.

HY-P99022

Gantenerumab	Amyloid-β	Neurological Disease
Gantenerumab is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab can be used for Alzheimer's disease research.

HY-P99185

Bapineuzumab	Amyloid-β	Neurological Disease
Bapineuzumab is an *anti-β-amyloid* protein (APP) monoclonal antibody**. Bapineuzumab can be used for the research of Alzheimer’s disease (AD).

HY-P99859

Donanemab LY3002813	Amyloid-β	Neurological Disease
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research.

HY-P99689

Lecanemab BAN-2401	Amyloid-β	Neurological Disease
Lecanemab (BAN-2401) is an IgG1 anti-soluble aggregated amyloid beta (Aβ) monoclonal antibody. Lecanemab shows activity across oligomers, protofibrils and insoluble fibrils. Lecanemab can be used for the research of Alzheimer's Disease.

HY-P99216

Ponezumab PF-04360365; RN 1219	EGFR	Neurological Disease
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease.

Cat. No.	Product Name	Target	Category

HY-P0265

*β-Amyloid* (1-40)**	Amyloid-β	Natural Products Source classification Endogenous metabolite
β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease.

HY-N8161

Kaempferol-3,7-di-O-β-glucoside Kaempferol 3,7-diglucoside	Glucosidase Cholinesterase (ChE)	Flavonoids Flavonols Phenols Polyphenols Source classification Plants other families
Kaempferol-3,7-di-O-β-glucoside (Kaempferol 3,7-diglucoside), a flavonol, possesses enzyme inhibition property towards α-amylase, α-glucosidase and Acetylcholinesterase. Kaempferol-3,7-di-O-β-glucoside protects differentiating neuronal cells, SH-SY5Y from Amyloid β peptide-induced injury. Kaempferol-3,7-di-O-β-glucoside has the potential for Alzheimer's research.

HY-W010041

Scyllo-Inositol	Amyloid-β Endogenous Metabolite	Structural Classification Natural Products Endogenous metabolite Source classification
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of *amyloid-β* peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model.

HY-W004287

Methyl tridecanoate	Amyloid-β Cholinesterase (ChE)	Natural Products Source classification Plants other families
Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE).

HY-N0225

(-)-Epigallocatechin Epigallocatechin; L-Epigallocatechin	MMP Autophagy	Flavanols Phenols Polyphenols Flavonoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Theaceae Camellia sinensis (L.) O. Ktze.
(-)-Epigallocatechin (Epigallocatechin) is the most abundant flavonoid in green tea, can bind to unfolded native polypeptides and prevent conversion to amyloid fibrils.

HY-N7887

Cassiaside	Beta-secretase	Phenols Polyphenols Source classification Plants Leguminosae seeds of Cassia tora Linn. other families
Cassiaside is a naphthopyrone glucoside, shows mixed-type inhibition against BACE1 (IC₅₀=4.45 μM; K_i=9.85 μM). Cassiaside possesses potential anti- Alzheimer's disease (AD) activity.

HY-N0663

Talatisamine	Potassium Channel	Alkaloids Pyrrole Alkaloids Source classification Plants Ranunculaceae Aconitum carmichaeli Debx.
Talatisamine, a aconitum alkaloid, is specific K⁺ channel blocker. Talatisamine attenuates beta-amyloid oligomers induced neurotoxicity in cultured cortical neurons.

HY-N7981

Pratensein	NF-κB	Flavonoids Isoflavones Phenols Polyphenols Source classification Plants Leguminosae Trifolium pratense L.
Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels.

HY-N7368

Hibifolin	Adenosine Deaminase	Flavonoids Flavonols Phenols Polyphenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Neurological Disease Source classification Plants other families
Hibifolin, a flavonol glycoside, is a potential inhibitor of adenosine deaminase (ADA), with a K_i of 49.92 μM. Hibifolin protects neurons against beta-amyloid-induced neurotoxicity.

HY-N2922

β-Amyrin	Amyloid-β	Structural Classification Monophenols Phenols Celastraceae Plants Celastrus hindsii Benth.
β-Amyrin, an ingredient of Celastrus hindsii, blocks amyloid β (Aβ)-induced long-term potentiation (LTP) impairment. β-amyrin is a promising candidate of treatment for AD.

HY-N0044

Ginsenoside Re Ginsenoside B2; Panaxoside Re; Sanchinoside Re	Amyloid-β NF-κB JNK Endogenous Metabolite	Triterpenes Terpenoids Neurological Disease Disease Research Fields Cancer Classification of Application Fields Source classification Plants Araliaceae Panax ginseng C. A. Meyer Endogenous metabolite
Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the *β-amyloid* protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.

HY-N1255

Scoulerine (-)-Scoulerine; Discretamine	Microtubule/Tubulin Beta-secretase Apoptosis	Alkaloids Isoquinoline Alkaloids Phenols Polyphenols Classification of Application Fields Disease Research Fields Cancer Source classification Plants other families
Scoulerine ((-)-Scoulerine), an isoquinoline alkaloid, is a potent antimitotic compound. Scoulerine is also an inhibitor of BACE1 (ß-site amyloid precursor protein cleaving enzyme 1). Scoulerine inhibits proliferation, arrests cell cycle, and induces apoptosis in cancer cells.

HY-N2898

Artanin	Cholinesterase (ChE)	Coumarins Phenylpropanoids Source classification Plants Rutaceae Zanthoxylum nitidum (Roxb.) DC.
Artanin is a coumarin, has biological activities related to Alzheimer’s disease. Artanin exerts function including AChE inhibitory and AChE- and self-induced amyloid beta (Aβ) aggregation inhibitory activities, with IC₅₀s of 51 μM, 98 μM, and 124 μM, respectively.

HY-N6904

Crocetin β-Crocetin	Amyloid-β	Terpenoids Diterpenoids Inflammation/Immunology Neurological Disease Disease Research Fields Classification of Application Fields Source classification Plants Lridaceae Crocus sativus L.
Crocetin (β-Crocetin), isolated from Crocus sativus, possesses anti-inflammatory, neuroprotective and antioxidant activity. Crocetin promotes clearance of *amyloid-β* by inducing autophagy via the STK11/LKB1-mediated AMPK pathway.

HY-N0249

Saikosaponin C	Amyloid-β	Terpenoids Triterpenes Source classification Plants Umbelliferae Bupleurum chinensis DC.
Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression.

HY-N1280

Semilicoisoflavone B	Amyloid-β	Flavonoids Isoflavones Phenols Polyphenols Source classification Plants Leguminosae Glycyrrhiza uralensis Fisch.
Semilicoisoflavone B, an isoflavone, mainly derived from Glycyrrhiza uralensis Fisch.. Semilicoisoflavone B reduces amyloid β (Aβ) secretion by inhibiting β-secretase-1 (BACE1) expression and activity. Semilicoisoflavone B decreases BACE1 expression mainly through increasing PPARγ expression and inhibiting STAT3 phosphorylation.

HY-N0061

Ethyl ferulate	Reactive Oxygen Species	Phenylpropanoids Monophenols Phenols Structural Classification Simple Phenylpropanols Umbelliferae Plants Source classification Ligusticum chuanxiong Hort.
Ethyl ferulate, a naturally lipophilic derivative of ferulic acid originally derived from Rhizoma Chuanxiong, induces heme oxygenase-1 (HO-1) and protects rat neurons against oxidative stress. Ethyl ferulate also protects neurons against amyloid β peptide (1-42)-induced oxidative stress and neurotoxicity.

HY-N6640

2-O-Acetyl-20-hydroxyecdysone 20-Hydroxyeedysone 2-acetate	Amyloid-β	Steroids Source classification Plants other families
2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β₄₂ (Aβ₄₂)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils.

HY-116753

(-)Clausenamide	Amyloid-β Tau Protein	Other Alkaloids Clausena lansium (Lour.) Skeels Rutaceae Plants Source classification
(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits *β-amyloid* (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ_25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD).

HY-113509

Lipoxin A4 LXA4	Interleukin Related Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Endogenous metabolite
Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC₅₀ value of 25.74 nM.

HY-N0373

Licochalcone B	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Chalcones Flavonoids Source classification Plants Leguminosae Glycyrrhiza uralensis Fisch.
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction.

HY-16561

Resveratrol trans-Resveratrol; SRT501	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2	Structural Classification Phenols Polyphenols
Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, *β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.

HY-N8376

Fustin (±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone	Amyloid-β mAChR Cholinesterase (ChE)	Flavonoids Flavanonols Source classification Plants Anacardiaceae Rhus glabra L.
Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) is a potent amyloid β (Aβ) inhibitor. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases the expression of acetylcholine (ACh) levels, choline acetyltransferase (ChAT) activity, and ChAT gene induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) decreases in acetyl cholinesterase (AChE) activity and AChE gene expression induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases muscarinic M1 receptor gene expression and muscarinic M1 receptor binding activity. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) can be used for Alzheimer's disease research.

Species:	Human (16) Mouse (5) Rat (1) Cat (1)
Tag:	His (17) Tag Free (2) GST (5) Fc (3)
Source:	HEK293 (8) P. pastoris (2) E. coli (13)

Cat. No.	Product Name	Species	Source

HY-P7501

Amyloid Precursor Protein, Human (HEK293, Fc) rHuamyloid Precursor, C-Fc; amyloid-Precursor	Human	HEK293
Amyloid Precursor Protein, Human (HEK293, Fc) is an Amyloid Precursor (APP) protein with C-Fc. Amyloid Precursor Protein can be used for the study of brain development, learning and memory, synaptic plasticity, and neurodegeneration.

HY-P75511

Amyloid Precursor/Beta-APP40 Protein, Human (His-GST)
amyloid-beta precursor protein; APP; Protease Nexin II; PreA4
Human E. coli
HY-P75512

Amyloid Precursor/Beta-APP39 Protein, Human (His-GST)
amyloid-beta precursor protein; APP; Protease Nexin II; PreA4
Human E. coli
HY-P75513

Amyloid Precursor/Beta-APP38 Protein, Human (His-GST)
amyloid-beta precursor protein; APP; Protease Nexin II; PreA4
Human E. coli
HY-P75582

APLP-1 Protein, Mouse (HEK293, His)
amyloid beta precursor like protein 1; amyloid-like protein 1; APLP-1; C30
Mouse HEK293
HY-P76168

APP/Protease Nexin II Protein, Human (His-GST)
amyloid-beta precursor protein; ABPP; PN-II; A4; AD1
Human E. coli

HY-P7502

APLP-1 Protein, Human (171a.a, HEK293, His) rHuamyloid-like Protein 1, His; APLP-1; amyloid-like Protein 1	Human	HEK293
APLP-1 Protein, Human (171a.a, HEK293, His), also known as APLP1, is increased in the frontal cortex of Mn-exposed models.

HY-P7522

APBA3 Protein, Human (His) rHuAPBA3, His; amyloid beta A4 precursor protein-binding family A member 3; APBA3	Human	E. coli
APBA3 Protein, Human (rHuAPBA3, His; Amyloid beta A4 precursor protein-binding family A member 3; APBA3) is an approximately 20.0 kDa APBA3 protein fused to His-tag. APBA3 Protein, Human (His) is an adapter protein that belongs to the X11 family and is involved in signal transduction processes.

HY-P72834

APP/Protease nexin-II Protein, Human (HEK293, Fc)
amyloid-beta precursor protein; APP; CVAP; PN-II; PreA4; A4; AD1
Human HEK293
HY-P77238

TM2D1 Protein, Human (HEK293, Fc)
TM2 domain-containing protein 1; amyloid-beta-binding protein; hBBP; BBP
Human HEK293
HY-P71780

Serum amyloid A protein, Cat (P.pastoris, His)
SAA1; Serum amyloid A protein
Cat P. pastoris

HY-P72240

IAPP Protein, Human (GST) Amylin; DAP; Diabetes associated peptide; Diabetes-associated peptide; IAP; IAPP; IAPP_HUMAN; Insulinoma amyloid peptide; Islet amyloid polypeptide diabetes associated peptide, amylin; ; Islet amyloid polypeptide	Human	E. coli

HY-P71809

Serum amyloid A-3 protein/Saa3 Protein, Mouse (P.pastoris, His)
Saa3; Serum amyloid A-3 protein
Mouse P. pastoris
HY-P71277

SAA4 Protein, Human (His)
Serum amyloid A-4 Protein; Constitutively Expressed Serum amyloid A Protein; C-SAA; SAA4; CSAA
Human E. coli
HY-P70660

SNCA Protein, Mouse
Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Snca
Mouse E. coli
HY-P70577

SNCA Protein, Human
Alpha-Synuclein; Non-A Beta Component of AD amyloid; Non-A4 Component of amyloid Precursor; NACP; SNCA; NACP; PARK1
Human E. coli
HY-P71327

SNCA Protein, Human (His)
Alpha-Synuclein; Non-A Beta Component of AD amyloid; Non-A4 Component of amyloid Precursor; NACP; SNCA; NACP; PARK1
Human E. coli
HY-P70985

SAA2 Protein, Human (His)
SAA; SAA2; Serum amyloid A2
Human E. coli
HY-P70510

SAA1 Protein, Human (His)
Serum amyloid A-1 Protein; SAA; SAA1
Human E. coli
HY-P700309

SAA1 Protein, Mouse (His)
Serum amyloid A-1 Protein; SAA; SAA1
Mouse E. coli
HY-P71111

Pentraxin 2 Protein, Mouse (HEK 293, His)
APCS; PTX2; SAP; 9.5S alpha-1-glycoprotein; Serum amyloid P; MGC88159; PTX2serum amyloid P-component; SAP pentaxin-related
Mouse HEK293
HY-P73715

Pentraxin 2/SAP Protein, Rat (HEK293, His)
Serum amyloid P-component; SAP; Apcs; Ptx2
Rat HEK293
HY-P71067

Pentraxin 2/SAP Protein, Human (HEK293, His)
Serum amyloid P-Component; SAP; 9.5S Alpha-1-Glycoprotein; APCS; PTX2
Human HEK293

Cat. No.	Product Name

HY-P0265AS

*β-Amyloid-15N (1-40) (TFA)*
β-Amyloid- 15N (1-40) (TFA) is the ¹⁵N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease[1].

HY-P1363S

*β-Amyloid-15N (1-42), human TFA*
β-Amyloid- 15N (1-42), human (TFA) is the ¹⁵N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease[1].

HY-137315S

TML-6-d3
TML-6-d₃ is the deuterium labeled TML-6. TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-

HY-W004287S

Methyl tridecanoate-d25
Methyl tridecanoate-d₂₅ is the deuterium labeled Methyl tridecanoate. Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE)[1].

HY-B0116S

Stavudine-d4
Stavudine-d₄ is the deuterium labeled Stavudine. Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis[1][2][3][4].

HY-113509S

Lipoxin A4-d5

Lipoxin A4-d₅ is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].

HY-16561S1

Resveratrol-13C6

Resveratrol-¹³C₆ is the ¹³C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-16561S

Resveratrol-d4

Resveratrol-d₄ is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-P0014S

Liraglutide-d8 triTFA

Liraglutide-d₈ (triTFA) is the deuterium labeled Liraglutide (HY-P0014)[1].

amyloid

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products